Literature DB >> 32151357

Management of Small Bowel Neuroendocrine Tumors.

Aaron T Scott1, James R Howe2.   

Abstract

Small bowel neuroendocrine tumors (SBNETS) are slow-growing neoplasms with a noted propensity toward metastasis and comparatively favorable prognosis. The presentation of SBNETs is varied, although abdominal pain and obstructive symptoms are the most common presenting symptoms. In patients with metastases, hypersecretion of serotonin and other bioactive amines results in diarrhea, flushing, valvular heart disease, and bronchospasm, termed carcinoid syndrome. The treatment of SBNETs is multimodal and includes surgery, liver-directed therapy, somatostatin analogues, targeted therapy, and peptide receptor radionuclide therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Neuroendocrine tumor; SBNET; Small bowel; Surgery

Year:  2020        PMID: 32151357     DOI: 10.1016/j.soc.2019.11.006

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

1.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 2.  Small bowel neuroendocrine neoplasm: what surgeons want to know.

Authors:  Akshya Gupta; Meghan G Lubner; Jason B Liu; Elizabeth S Richards; Perry J Pickhardt
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

3.  Mesenteric venous thrombosis: a rare complication of small bowel neuroendocrine tumor presenting with gangrenous appendicitis.

Authors:  Arshad M Bachelani
Journal:  J Surg Case Rep       Date:  2022-03-22

Review 4.  Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Giuseppe Iabichino; Milena Di Leo; Monica Arena; Giovanni Giuseppe Rubis Passoni; Elisabetta Morandi; Francesca Turpini; Paolo Viaggi; Carmelo Luigiano; Luca De Luca
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.